In conclusion, we show that targeting CTLA-4 within the initial tumor fragment cultures for ACT in ovarian cancer, increases TIL proliferation and favors the expansion of tumor-reactive CD8+ TILs. The gene discussed is CD8A; the disease is ovarian carcinoma.